O52 Plasma circulating cell-free messenger RNA as a potential biomarker of melanoma

Abstract Introduction Blood-borne cell-free nucleic acids are increasingly emerging as significant non-invasive adjuncts to current methods of disease status evaluation in cancer patients. In this study, we sought examine whether differences exist the plasma transcriptomic profile advanced melanoma patients with a high burden compared therapeutic response. Method Plasma circulating messenger ribonucleic acid (ccfmRNA) was extracted from twenty stage IV receiving immunotherapy. Pathway focused gene expression analysis performed. Patients were assessed paired blood sample collection and CT scan assessments at baseline 3 months follow up. Response Evaluation Criteria Solid Tumours (RECIST 1.1) used for tumour estimation. Result patients, CCL5, GZMB MYD88 genes significantly over-expressed (P < 0.05 versus healthy controls). or progressive disease, CCL18, CCR1, CCR4, CD274, CSF2, GBP1 response). Finally, brain metastases, EGF, GBP1, PTGS2 0.05, without metastasis). Conclusion Significant observed between various patient groups, postulate that these may be exploited identify novel targets biomarkers relevant melanoma. CCL4 CCL5 prognostic melanoma, both had higher expressions low burden. Take-home Message ccfmRNA transcripts High is favourable